诱导多能干细胞分化的心肌细胞在心脏毒性评价中的应用

药物研发失败的重要原因之一是由于其心脏毒性，其中许多原因归因于临床前动物模型未能预见人体中的心脏毒性作用，这是制药工业面临的重大问题。自从2006年诱导性多能干细胞（iPSCs）技术取得突破性的发现以来，对药物研发领域产生了巨大的影响。iPSCs在心肌损伤修复、心血管疾病相关模型的建立和治疗药物筛选等方面表现出明显的优势和应用前景。本文综述了iPSCs技术在心脏毒性评价中的一些应用并讨论了未来的方向和面临的挑战。

One of the most important reasons for the failure of drug development is its cardiac toxicity,many of which attributed to preclinical animal models incapable of foreseeing cardiotoxic side effects of the drugs being tested in humans.The emergence of induced pluripotent stem cells (iPSCs) technology has had a great impact on the field of medicine ever since the ground-breaking discovery in 2006.iPSCs has certainly advantages and application prospects in myocardial injury repair,establishing cardiovascular disease-related model and drug screening.The application of iPSCs technology in cardiac toxicity evaluation has been reviewed in this paper,and the future directions and ongoing challenges ahead in this exciting field has also been discussed.